Ratiopharm reduces Teva's dependency on Copaxone in Q3
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries' recent acquisition, the German company Ratiopharm for which Teva paid $3.6 billion in August, accounted for 45% of the Israeli firm's net sales growth in the third quarter. Teva's total sales were up by $700 million to $4.3 billion, a 20% increase over the same quarter in 2009. Ratiopharm, Germany's second-largest producer of generics and biosimilar pharmaceuticals, added around $315 million in revenues since Teva acquired it.